In vitro and in vivo enhancement of ddI activity against Rauscher murine leukemia virus by ribavirin.
Ribavirin has been reported to enhance the activity of ddI against HIV. We explored this enhancement of antiviral activity in Rauscher murine leukemia virus (RMuLV) models in vitro and in vivo. The significant finding in these studies was that combinations of the drugs exhibited virus titer reductions that were greater than would be expected if the drug interactions were simply additive. These effects were designated synergistic by the method of Prichard and Shipman (Prichard, M.N. and Shipman, C., Jr. (1990). A three-dimensional model to analyze drug-drug interaction, Antiviral Res. 14, 181-206). In addition to the antiviral synergy, we also observed some synergistic toxicity in the animal model.
Microbiology Research Department, Southern Research Institute, Birmingham, AL 35205, USA.
L B
LB
Allen
D C
DC
Quenelle
L
L
Westbrook
B A
BA
Taylor
M N
MN
Prichard
A D
AD
Brazier
M G
MG
Hollingshead
W M
WM
Shannon
D000818:Animals; D002460:Cell Line; D016049:Didanosine / Q000494:pharmacology*; D004357:Drug Synergism; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000821:virology; D008297:Male; D051379:Mice; D011925:Rauscher Virus / Q000187:drug effects* / Q000302:isolation & purification; D012192:Retroviridae Infections / Q000188:drug therapy*; D012254:Ribavirin / Q000494:pharmacology*; D014412:Tumor Virus Infections / Q000188:drug therapy*; D015430:Weight Gain
D012254:Ribavirin; D016049:Didanosine